Literature DB >> 27045927

Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease.

Lawrence S Gaines1,2, James C Slaughter3, Sara N Horst1, David A Schwartz1, Dawn B Beaulieu1, Kirsten L Haman2, Li Wang3, Christopher F Martin4, Millie D Long4, Robert S Sandler4, Michael D Kappelman5.   

Abstract

OBJECTIVES: The prevalence of depression is high in patients with Crohn's disease (CD). We examined the influence of affective-cognitive symptoms of depression on the risk of exacerbation of CD.
METHODS: We studied 2,144 adult volunteers with a self-reported diagnosis of CD who completed a baseline survey that included demographics, CD status, and an affective-cognitive index of depression. Linear and logistic regression analyses were used to determine whether CD status at 12 months was associated with the baseline measure of depression. Analyses were adjusted for confounders including age, gender, race, baseline disease activity, disease duration, prior hospitalization and surgery, corticosteroid and anti-TNF use, medication adherence, body mass index, current smoking, education, and sleep quality.
RESULTS: Depression was significantly associated with subsequent increases in SCDAI score in both unadjusted (P<0.001) and adjusted (P<0.001) analyses. This association was non-linear, with a shallower slope for lower levels of depression. A 10-point increase in depression t-scores from 55 to 65 was associated with a 18.6-point increase in SCDAI (95% CI 11.5-25.6) and an odds ratio of 1.27 for SCDAI>150 at follow-up (CI: 1.01-1.60). We also found a significant association between depressive symptoms and hospitalization.
CONCLUSIONS: Cognitive-affective depressive symptoms were significantly associated with a risk of exacerbation of CD and hospitalization.

Entities:  

Mesh:

Year:  2016        PMID: 27045927      PMCID: PMC4965803          DOI: 10.1038/ajg.2016.98

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  20 in total

1.  Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results.

Authors:  Millie D Long; Michael D Kappelman; Christopher F Martin; James D Lewis; Lloyd Mayer; Patricia M Kinneer; Robert S Sandler
Journal:  Inflamm Bowel Dis       Date:  2012-01-27       Impact factor: 5.325

2.  The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.

Authors:  P Persoons; S Vermeire; K Demyttenaere; B Fischler; J Vandenberghe; L Van Oudenhove; M Pierik; T Hlavaty; G Van Assche; M Noman; P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  2005-07-15       Impact factor: 8.171

Review 3.  The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review.

Authors:  E V Loftus; P Schoenfeld; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

4.  Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity.

Authors:  Houssam E Mardini; Kevin E Kip; John W Wilson
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

5.  Depression subtypes in pediatric inflammatory bowel disease.

Authors:  Eva M Szigethy; Ada O Youk; David Benhayon; Diane L Fairclough; Melissa C Newara; Margaret A Kirshner; Simona I Bujoreanu; Christine Mrakotsky; Athos Bousvaros; Arvind I Srinath; David J Keljo; David J Kupfer; David R DeMaso
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-05       Impact factor: 2.839

6.  Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study.

Authors:  Christian Mittermaier; Clemens Dejaco; Thomas Waldhoer; Anna Oefferlbauer-Ernst; Wolfgang Miehsler; Markus Beier; Wolfgang Tillinger; Alfred Gangl; Gabriele Moser
Journal:  Psychosom Med       Date:  2004 Jan-Feb       Impact factor: 4.312

7.  The influence of depression on quality of life in patients with inflammatory bowel disease.

Authors:  Clarence K Zhang; Jennifer Hewett; Jason Hemming; Taneisha Grant; Hongyu Zhao; Clara Abraham; Ioannis Oikonomou; Meera Kanakia; Judy H Cho; Deborah D Proctor
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

8.  Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study.

Authors:  Ashwin N Ananthakrishnan; Hamed Khalili; An Pan; Leslie M Higuchi; Punyanganie de Silva; James M Richter; Charles S Fuchs; Andrew T Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-31       Impact factor: 11.382

Review 9.  Epidemiology and treatment of depression in patients with chronic medical illness.

Authors:  Wayne J Katon
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

10.  Associations between depression and diabetes in the community: do symptom dimensions matter? Results from the Gutenberg Health Study.

Authors:  Jörg Wiltink; Matthias Michal; Philipp S Wild; Astrid Schneider; Jochem König; Maria Blettner; Thomas Münzel; Andreas Schulz; Matthias Weber; Christian Fottner; Norbert Pfeiffer; Karl Lackner; Manfred E Beutel
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

View more
  21 in total

1.  Multidisciplinary Team-Based Approaches to IBD Management: How Might "One-Stop Shopping" Work for Complex IBD Care?

Authors:  Chang Kyun Lee; Gil Y Melmed
Journal:  Am J Gastroenterol       Date:  2017-05-16       Impact factor: 10.864

2.  Psychiatric comorbidities in patients with inflammatory bowel disease.

Authors:  Rasika Bhamre; Sangeet Sawrav; Shilpa Adarkar; Rishika Sakaria; Shobna J Bhatia
Journal:  Indian J Gastroenterol       Date:  2018-09-08

3.  Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease.

Authors:  Cong Dai; Min Jiang; Ming-Jun Sun
Journal:  Am J Gastroenterol       Date:  2016-08       Impact factor: 10.864

4.  Reply to Dai et al.

Authors:  Lawrence S Gaines; Michael D Kappelman; Millie Dascomb Long
Journal:  Am J Gastroenterol       Date:  2016-08       Impact factor: 10.864

5.  Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.

Authors:  Betsy W Stevens; Nynke Z Borren; Gabriella Velonias; Grace Conway; Thom Cleland; Elizabeth Andrews; Hamed Khalili; John G Garber; Ramnik J Xavier; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2016-10-28       Impact factor: 3.199

6.  Does Reverse Causality Underlie the Temporal Relationship Between Depression and Crohn's Disease?

Authors:  Lawrence S Gaines; James C Slaughter; David A Schwartz; Dawn B Beaulieu; Sara N Horst; Robin L Dalal; Elizabeth A Scoville; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2020-02-11       Impact factor: 5.325

Review 7.  Modifiable Environmental Factors in Inflammatory Bowel Disease.

Authors:  Kristin E Burke; Christine Boumitri; Ashwin N Ananthakrishnan
Journal:  Curr Gastroenterol Rep       Date:  2017-05

8.  Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) Symptom Scales in Subjects With Inflammatory Bowel Diseases.

Authors:  Bharati Kochar; Christopher F Martin; Michael D Kappelman; Brennan M Spiegel; Wenli Chen; Robert S Sandler; Millie D Long
Journal:  Am J Gastroenterol       Date:  2017-08-29       Impact factor: 10.864

9.  ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Authors:  Gary R Lichtenstein; Edward V Loftus; Kim L Isaacs; Miguel D Regueiro; Lauren B Gerson; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2018-03-27       Impact factor: 10.864

10.  High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease.

Authors:  Edward L Barnes; Millie D Long; Michael D Kappelman; Christopher F Martin; Robert S Sandler
Journal:  Inflamm Bowel Dis       Date:  2019-06-18       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.